FibroGen To Pay SEC $1.25M Over Drug Mistatements

Biopharmaceutical company FibroGen Inc. has agreed to pay a $1.25 million penalty to the U.S. Securities and Exchange Commission to resolve claims that its former chief medical officer fudged results for...

Already a subscriber? Click here to view full article